Pharmacokinetics and Safety Study of YZJ-1139 in Subjects With Mild, Moderate and Normal Hepatic Impairment
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2024-11-04
- Target Recruit Count
- 24
- Registration Number
- NCT06671509
- Locations
- π¨π³
The First Hospital of Jilin University, Changchun, Jilin, China
Pharmacokinetics and Safety Study of YZJ-1139 in Subjects With Severe Renal Impairment and Normal Renal Impairment
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2024-11-04
- Target Recruit Count
- 16
- Registration Number
- NCT06671444
- Locations
- π¨π³
Zhongda Hospital Southeast University, Nanjing, Jiangsu, China
π¨π³The First Affiliated Hospital of Bengbu Medical University, Bengbu, China
π¨π³The First Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
A Phase 1 Study of YZJ-5053 Tablets in Participants With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Solid Tumor
- Interventions
- Drug: YZJ-5053 tablets
- First Posted Date
- 2024-01-17
- Last Posted Date
- 2024-01-17
- Target Recruit Count
- 157
- Registration Number
- NCT06209385
- Locations
- π¨π³
Shanghai East Hospital, Shanghai, Shanghai, China
π¨π³Shandong Cancer Hospital, Jinan, Shandong, China
π¨π³The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Safety and Efficacy Study of YZJ-1139 in Insomnia Disorder
Phase 3
Recruiting
- Conditions
- Insomnia Disorder
- Interventions
- Drug: PlaceboDrug: YZJ-1139 20mgDrug: YZJ-1139 40mg
- First Posted Date
- 2022-09-01
- Last Posted Date
- 2024-04-18
- Target Recruit Count
- 1041
- Registration Number
- NCT05525637
- Locations
- π¨π³
WuXi People's Hospital, Wuxi, China
π¨π³HeNan University Of Science &Technology, Luoyang, China
π¨π³NingBo KangNing Hospital, Ningbo, China
Β© Copyright 2025. All Rights Reserved by MedPath